Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

NACompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

January 2, 2020

Study Completion Date

February 7, 2022

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
RADIATION

iSABR, 25 Gray in 1 fraction for small peripheral tumors

Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.

RADIATION

iSABR, 50 Gray in 4 fractions for medium peripheral tumors

Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.

RADIATION

iSABR, 54 Gray in 3 fractions for large peripheral tumors

Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.

RADIATION

iSABR, 40 Gray in 4 fractions for small central tumors

Radiotherapy procedure for participants with small central tumors ≤ 10 cc.

RADIATION

iSABR, 50 Gray in 4 fractions for medium central tumors

Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.

RADIATION

iSABR, 60 Gray in 8 fractions for large central tumors

Radiotherapy procedure for participants with large central tumors \> 30 cc.

Trial Locations (4)

94305

Stanford University Cancer Institute, Stanford

98104

Swedish Cancer Institute, Seattle

ON M5G 2M9

Princess Margaret Cancer Center, Toronto

Unknown

Hokkaido University Hospital, Sapporo

All Listed Sponsors
lead

Stanford University

OTHER

NCT01463423 - Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | Biotech Hunter | Biotech Hunter